Dr Martin Kaiser is a Clinician Scientist and Honorary Consultant Haematologist at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust. In 2018, he became Team Leader of the Myeloma Molecular Therapy Group at the ICR.
He graduated with a degree in medicine from the University of Aachen (RWTH), Germany, in 2004 where he also obtained an MD in Pathology for research on multiple myeloma microenvironment interactions.
Dr Kaiser specialised in Haemato-Oncology at Charité University Medicine Berlin, Germany where he also pursued research in multiple myeloma and leukaemia. He was awarded a research fellowship by DFG (Deutsche Forschungsgemeinschaft) in 2011 and joined the ICR for a postdoctoral research project in myeloma epigenetics. He was appointed Clinician Scientist and Honorary Consultant Haematologist in 2014 at the ICR and RMH and was awarded Fellowship of the Royal College of Physicians and the Royal College of Pathology in 2018.
His main research interest is the molecular characterisation of multiple myeloma, an immune cell cancer of the bone marrow, with the aim of designing gentler therapies tailored to patients’ needs. His team is working on state-of-the-art genetic profiling to gain insight into the evolution of myeloma and the development of treatment resistance.
In collaboration with Dr Christina Messiou at The Royal Marsden Hospital and the ICR he is investigating the connection between molecular genetics and disease presentation using advanced functional, diffusion-weighted MRI imaging technology. A particular focus of his work is high-risk myeloma.
Dr Kaiser is chief investigator of the national OPTIMUM trial, which offers tailored therapy for patients with molecular high-risk disease. He is active member of the UK NCRI group, the UK Myeloma Research Alliance (UKMRA) network and the UK Myeloma Forum and serves as principal or co-investigator for several national and international myeloma trials.
In July 2018, Martin became the first Jacquelin Forbes-Nixon Research Fellow. This was announced by the David Forbes-Nixon Charitable Foundation who are funding research to find a cure for myeloma. The establishment of the Fellowship marks a significant milestone in working towards achieving this goal.